Fig. 5: Multivariable analysis of factors associated with disease control and survival.

Forest plot for a progression-free and b overall survival in multivariable Cox regression analysis in the cohort of patients with stage III NSCLC treated with concurrent chemoradiation and durvalumab. Data are presented as the hazard ratio (HR) with error bars showing 95% confidence interval. Cox proportional hazards regression models were applied to calculate the HR. Eastern Cooperative Oncology Group performance status (ECOG PS), neutrophil-to-lymphocyte ratio (NLR), tumor mutation burden (TMB), and PD-L1 tumor proportion score (TPS). Source data are provided as a Source Data file.